Lung cancer is the second most common cancer in both men and women. More than one million lung cancer cases are diagnosed worldwide each year. It has the highest death rate among all types of cancers in the United States and worldwide. Early detection with higher yield tissue diagnosis as well as an accurate localization during lung interventions may help reduce the impact, death rate, and overall population cost of lung cancer. Accurate and timely clinical information facilitates patient-specific therapy decisions, resulting improved clinical outcomes. Engineering approaches that are low cost and also Accurate localization of biopsy devices alongside of verification that biopsy needle is within solid abnormal tissue (and not normal non-target lung) can signi?cantly improve the accuracy of the diagnosis, which further helps clinicians make the optimal decision via a lung treatment decision tree.